Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.

Autor: Comber L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O Murchu E; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Jordan K; Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Information and Quality Authority (HIQA), Dublin, Ireland., Teljeur C; Health Information and Quality Authority (HIQA), Dublin, Ireland., Ryan M; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Health Sciences, Dublin, Ireland., Carnahan A; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Public Health Agency of Sweden, Solna, Sweden., Pérez Martín JJ; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; General Directorate of Public Health and Addictions, IMIB-Arrixaca, Murcia University, Region of Murcia, Spain., Robertson AH; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., de Jonge J; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands., Krause T; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Nohynek H; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Pediatric Research Laboratory, School of Health Sciences, Faculty of Nursing, National & Kapodistrian University of Athens, Goudi, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Soler-Soneira M; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Harrington P; Health Information and Quality Authority (HIQA), Dublin, Ireland.
Jazyk: angličtina
Zdroj: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2330. Date of Electronic Publication: 2022 Feb 04.
DOI: 10.1002/rmv.2330
Abstrakt: This review sought to assess the efficacy, effectiveness and safety of high-dose inactivated influenza vaccines (HD-IIV) for the prevention of laboratory-confirmed influenza in individuals aged 18 years or older. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) were included. The search returned 28,846 records, of which 36 studies were included. HD-IIV was shown to have higher relative vaccine efficacy in preventing influenza compared with standard-dose influenza vaccines (SD-IIV3) in older adults (Vaccine effectiveness (VE) = 24%, 95% CI 10-37, one RCT). One NRSI demonstrated significant effect for HD-IIV3 against influenza B (VE = 89%, 95% CI 47-100), but not for influenza A(H3N2) (VE = 22%, 95% CI -82 to 66) when compared with no vaccination in older adults. HD-IIV3 showed significant relative effect compared with SD-IIV3 for influenza-related hospitalisation (VE = 11.8%, 95% CI 6.4-17.0, two NRSIs), influenza- or pneumonia-related hospitalisation (VE = 13.7%, 95% CI 9.5-17.7, three NRSIs), influenza-related hospital encounters (VE = 13.1%, 95% CI 8.4-17.7, five NRSIs), and influenza-related office visits (VE = 3.5%, 95% CI 1.5-5.5, two NRSIs). For safety, HD-IIV were associated with significantly higher rates of local and systemic adverse events compared with SD-IIV (combined local reactions, pain at injection site, swelling, induration, headache, chills and malaise). From limited data, compared with SD-IIV, HD-IIV were found to be more effective in the prevention of laboratory-confirmed influenza, for a range of proxy outcome measures, and associated with more adverse events.
(© 2022 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: